We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.065 | 4.10% | 1.65 | 1.622 | 1.678 | 1.68 | 1.622 | 1.65 | 1,887,786 | 16:35:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.80 | 19.19M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/1/2023 11:05 | Another very good bit of news today.... | the chairman elect | |
04/1/2023 10:56 | OCTP looks a better bet, with Phase 1 starting this month and their cannabinoid trials being cheaper and quicker than for HEMO's drugs. | idriveajag | |
10/12/2022 01:34 | Question...?What is black and white, wise and guarded..? And avoids, where possible, coming in to direct contact with humans..??Answer: The eyesight of a dog.Oh... and... The Badger...!!! | bahamarama | |
18/11/2022 17:00 | Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second and final Process Development ("PD") run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms. This is another step for the Company in its preparation of the Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") required to authorise commencement of Phase I clinical trials of HEMO-CAR-T. The Company's amazing team of scientists is now moving toward engineering runs (Process Qualification) of HEMO-CAR-T cell production. | the chairman elect | |
18/11/2022 16:37 | HEMO-CAR-T Process Development Runs Completed Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second and final Process Development ("PD") run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The process was carried out in the Company's current Good Manufacturing Practice ("cGMP") compliant clean rooms. This is another step for the Company in its preparation of the Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") required to authorise commencement of Phase I clinical trials of HEMO-CAR-T. The Company's amazing team of scientists is now moving toward engineering runs (Process Qualification) of HEMO-CAR-T cell production. | ashleyjv | |
08/11/2022 00:51 | jotohaI won't be kicking myself because 8pps is never gonna happen........unless MadVlad consolidates the shares. | badger60 | |
04/11/2022 07:46 | Very cryptic comment. | lean5gb | |
04/11/2022 07:17 | How big is the overnight news? | trying2trade | |
01/11/2022 11:57 | You certainly will be kicking yourself when it hits 8p again boom boom . | jotoha2 | |
27/10/2022 14:10 | Do you ever get that feeling that other people know something you don't? I'm getting that feeling with HEMO today. 54 transactions, nearly all buys | ashleyjv | |
27/10/2022 12:59 | Buy out coming :-) | orchestralis | |
27/10/2022 12:28 | Are we ready to launch this finally . | jotoha2 | |
24/10/2022 14:56 | Get over yourself Tom. | david gruen | |
24/10/2022 14:35 | The HEMO has awoken from its recent slumber! | the chairman elect | |
27/9/2022 15:00 | Baldrick..you have embarrassed yourself with that tip for VAL...what a nob ! | davevtsmummy | |
26/9/2022 00:00 | Today BUYING stock MCL (LSE) | blackhorse23 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions